Welcome to our dedicated page for Sartorius news (Ticker: SARTF), a resource for investors and traders seeking the latest updates and insights on Sartorius stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sartorius's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sartorius's position in the market.
Sartorius, based in Göttingen, Germany, projects strong growth in the first half of 2021, estimating revenue growth of approximately 60% in constant currencies. They anticipate an underlying EBITDA margin slightly above 34%. The Bioprocess Solutions Division expects a 63% revenue increase, while the Lab Products & Services Division is estimated to grow by 52%. Following this performance, Sartorius has raised its full-year sales growth forecast to around 45%. The company will release detailed half-year figures on July 21, 2021.
Sartorius has acquired a 51% stake in CellGenix GmbH for approximately 100 million euros, enhancing its capabilities in cell and gene therapy production. This acquisition, with plans to acquire the remaining shares by 2026, positions Sartorius to leverage CellGenix's expertise and reputation in the biopharma sector. CellGenix generated over 20 million euros in sales in 2020, boasting a strong EBITDA margin. Sartorius aims to expand the Freiburg site as a center of excellence for quality-critical raw materials, aiming to accelerate drug development timelines.
Sartorius Stedim Biotech reported a strong start to fiscal 2021 with sales revenue rising 61.1% to 655 million euros, driven by demand from vaccine manufacturers and acquisitions. Order intake nearly doubled to 1,004 million euros, reflecting changing customer ordering patterns. Underlying EBITDA increased 82.8% to 232 million euros with a margin of 35.4%. The company confirmed its full-year forecast projecting 38% sales growth and a 33% EBITDA margin.
Sartorius released its annual report, confirming a 30.2% surge in group sales revenue to nearly 2,336 million euros for 2020. Order intake increased 49.0%, reaching 2,836 million euros, driven largely by pandemic-related demand. The underlying EBITDA rose 39.6% to 692 million euros, with a margin climbing to 29.6%. The company expects continued strong growth in 2021, projecting sales revenue to increase by 19% to 25%. Sartorius aims to achieve 5 billion euros in sales by 2025, with significant expansions in production capabilities.
FAQ
What is the current stock price of Sartorius (SARTF)?
What is the market cap of Sartorius (SARTF)?
